Skip to main content

Table 3 Pooled estimates in MSCs group and no MSCs group

From: Mesenchymal stromal cells as prophylaxis for graft-versus-host disease in haplo-identical hematopoietic stem cell transplantation recipients with severe aplastic anemia?—a systematic review and meta-analysis

Pooled estimates Pooling model Number of studies, haplo-HSCT + MSCs/haplo-HSCT alone haplo-HSCT + MSCs (95% CI) haplo-HSCT alone (95% CI) OR (95% CI) p value
aGVHD Fixed/random 7/9 56.0% (48.6%, 63.5%) 47.2% (29.0%, 65.4%) 1.43 (0.91–2.25) 0.123
Grade II–IV aGVHD Fixed/random 8/20 29.8% (24.1%, 35.5%) 30.6% (26.6%,34.6%) 0.97 (0.70–1.32) 0.889
cGVHD Fixed/random 8/18 25.4% (19.8%, 31.0%) 30.0% (23.3%,36.6%) 0.79 (0.56–1.11) 0.187
2-year OS Fixed/fixed 8/12 84.9% (80.4%, 89.3%) 85.2% (81.6%,88.8%) 0.98 (0.60–1.61) 1.000
Engraftment rate Fixed/fixed 8/17 98.9% (96.4%, 100.0%) 98.6% (96.5%,99.8%) 1.02 (0.66–1.54) 1.000
CMV infection rate Random/random 5/10 52.4% (31.6–73.1%) 64.1% (52.9–75.2%) 0.61 (0.40–1.92) 0.018
  1. Abbreviations: GVHD graft-versus-host disease, aGVHD acute GVHD, cGVHD chronic GVHD, MSCs mesenchymal stromal cells, haplo-HSCT haplo-identical hematopoietic stem cell transplantation, OR odds ratio, OS overall survival, CI confidence interval, CMV cytomegalovirus